Lilly's $7B Kelonia Deal Reshapes In Vivo CAR-T Supply Chains

Eli Lilly and Company has agreed to acquire Kelonia Therapeutics in a deal valued at $7 billion, a transaction that positions the Indianapolis-based manufacturer to secure proprietary in vivo CAR-T cell therapy capabilities and, by extension, forces a reassessment of how the broader industry approaches advanced therapy medicinal product (ATMP) manufacturing infrastructure.

For plant heads and QA directors already navigating the GMP complexity of autologous and allogeneic cell therapy platforms, the acquisition signals a directional shift: large integrated pharma is moving to internalize in vivo CAR-T manufacturing rather than rely on contract development and manufacturing organizations (CDMOs). That strategic posture, if replicated across the sector, carries direct consequences for ATMP contract manufacturing demand and for the capital investment decisions currently being made around cleanroom capacity, closed-system processing, and sterility assurance protocols aligned with ICH Q10 and 21 CFR Part 211.

In vivo CAR-T approaches, which aim to engineer T-cells directly inside the patient rather than through ex vivo manipulation, present a distinct GMP challenge set compared to conventional cell therapy. Eliminating the apheresis-to-manufacturing-to-reinfusion chain reduces certain contamination and chain-of-identity risks, but introduces new process validation requirements around vector delivery, in-patient transduction efficiency, and release testing paradigms that current regulatory frameworks are still adapting to accommodate.

The deal, announced April 20, 2026, underscores Lilly's intent to control the manufacturing science at the earliest stage of what many regulatory affairs leads regard as the next inflection point in oncology biologics. For CDMOs that have invested heavily in ATMP suites anticipating outsourced demand from innovator companies, the acquisition raises a pointed question about whether the largest sponsors will ultimately bring this manufacturing capability in-house as the technology matures.

Source: This article is based on reporting from Pharmaceutical Industry News (EIN Presswire, published April 21, 2026). The source material provided limited operational detail; Pharma Now will update this report as further disclosures become available.